The Secretary FCT Health & Human Services Secretariat (HHSS), Barr. Amanda Pam, held an inaugural meeting of a ten (10) man ministerial committee to fashion out ways for the Administration to achieve contract manufacturing of essential medicine, to ensure that drugs are henceforth available at all FCT hospitals health facilities at affordable cost, guarantee quality and branded for FCT.
In her remarks, the Secretary said the management Team of the Secretariat had several high level meetings with the various Managing Directors and Chief Executives of local Pharmaceutical industries.
She added that the focus of the meeting was to demonstrate leadership commitment of the Administration to the project, understanding the company’s capacity to deliver on quality and competence and the ready market available in the FCT Administration’s facilities as well volume of products envisaged to bring reduction without compromising quality.
According to Pam, “all the Chief executives signified their buy-in and applauded the administration laudable concept that will see to the growth of local industries in the country.
“Following the agreement to work towards actualization of the concept, the Chief executive directed their respective representatives to make presentations to the Technical Committee within the shortest possible time.
“Some of the advantages to be derived from the committee are that it is going to be a win-win situation for both the administration, availability of quality assured products, readily available products, it will also reduce cost of the products because of direct engagement and bulk purchase.
“Others include pocket friendly retail prices of essential medicines at all the FCTA hospitals and the companies will have ready market, volume sales, cut-off marketing and logistics of supply chain.”
She adds: “The terms of reference of the committee include to study the proposal for contract manufacturing, evaluate its operationalization, and evaluate the modalities and system requirement.
“It includes peer review of states involved in contract manufacturing. Others are to evaluate the financial implication and make recommendations.”